1. Home
  2. TRMD vs ADPT Comparison

TRMD vs ADPT Comparison

Compare TRMD & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TORM plc

TRMD

TORM plc

HOLD

Current Price

$30.28

Market Cap

2.9B

ML Signal

HOLD

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$22.27

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRMD
ADPT
Founded
1889
2009
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
2.7B
IPO Year
2016
2019

Fundamental Metrics

Financial Performance
Metric
TRMD
ADPT
Price
$30.28
$22.27
Analyst Decision
Buy
Strong Buy
Analyst Count
1
9
Target Price
$35.00
$17.78
AVG Volume (30 Days)
629.4K
2.9M
Earning Date
05-13-2026
05-05-2026
Dividend Yield
6.61%
N/A
EPS Growth
N/A
63.89
EPS
N/A
N/A
Revenue
N/A
$276,976,000.00
Revenue This Year
N/A
$3.98
Revenue Next Year
N/A
$22.72
P/E Ratio
$9.61
N/A
Revenue Growth
N/A
54.77
52 Week Low
$18.00
$9.96
52 Week High
$35.33
$23.15

Technical Indicators

Market Signals
Indicator
TRMD
ADPT
Relative Strength Index (RSI) 57.38 60.64
Support Level $29.15 $15.08
Resistance Level $30.62 $22.97
Average True Range (ATR) 0.84 1.25
MACD 0.24 -0.14
Stochastic Oscillator 86.24 77.51

Price Performance

Historical Comparison
TRMD
ADPT

About TRMD TORM plc

TORM PLC operates as a shipping company mainly owning and operating a fleet of product tankers. It is engaged in the transportation of refined oil products and clean petroleum products, including gasoline, jet fuel, naphtha, and diesel oil. The Company operates through two segments: the Tanker segment and the Marine Engineering segment, deriving the majority of its revenue from the Tanker segment.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Share on Social Networks: